Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global NEISSERIA MENINGITIDIS INFECTIONS DRUG market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
NEISSERIA MENINGITIDIS INFECTIONS DRUG market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The NEISSERIA MENINGITIDIS INFECTIONS DRUG market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the NEISSERIA MENINGITIDIS INFECTIONS DRUG products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of NEISSERIA MENINGITIDIS INFECTIONS DRUG products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the NEISSERIA MENINGITIDIS INFECTIONS DRUG market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on NEISSERIA MENINGITIDIS INFECTIONS DRUG development has been the leading industry trend of NEISSERIA MENINGITIDIS INFECTIONS DRUG market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
MGBBP-3,NCL-195,TP-10,Others |
| By Application Outlook |
Hospital,Clinic,Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Beijing Minhai Biotechnology Co Ltd,Biological E Ltd,China National Pharmaceutical Group Corp,GlaxoSmithKline Plc,Griffith University,ImmunoBiology Ltd,JN-International Medical Corp,MGB Biopharma Ltd,Panacea Biotec Ltd,Pfizer Inc,Sanofi Pasteur SA,Serum Institute of India Ltd,Wellstat Vaccines LLC |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Beijing Minhai Biotechnology Co Ltd
- Biological E Ltd
- China National Pharmaceutical Group Corp
- GlaxoSmithKline Plc
- Griffith University
- ImmunoBiology Ltd
- JN-International Medical Corp
- MGB Biopharma Ltd
- Panacea Biotec Ltd
- Pfizer Inc
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Wellstat Vaccines LLC
NEISSERIA MENINGITIDIS INFECTIONS DRUG Market, By Type
- MGBBP-3
- NCL-195
- TP-10
- Others
NEISSERIA MENINGITIDIS INFECTIONS DRUG Market, By Application
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 NEISSERIA MENINGITIDIS INFECTIONS DRUG Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 MGBBP-3 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 NCL-195 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 TP-10 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Type
8.1 Asia Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Application (Consumption and Market Share)
8.2 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Application (Consumption and Market Share)
8.3 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Application (Consumption and Market Share)
8.4 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Beijing Minhai Biotechnology Co Ltd
9.1.1 Beijing Minhai Biotechnology Co Ltd Profiles
9.1.2 Beijing Minhai Biotechnology Co Ltd Product Portfolio
9.1.3 Beijing Minhai Biotechnology Co Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.1.4 Beijing Minhai Biotechnology Co Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.2 Biological E Ltd
9.2.1 Biological E Ltd Profiles
9.2.2 Biological E Ltd Product Portfolio
9.2.3 Biological E Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.2.4 Biological E Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.3 China National Pharmaceutical Group Corp
9.3.1 China National Pharmaceutical Group Corp Profiles
9.3.2 China National Pharmaceutical Group Corp Product Portfolio
9.3.3 China National Pharmaceutical Group Corp NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.3.4 China National Pharmaceutical Group Corp NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.4 GlaxoSmithKline Plc
9.4.1 GlaxoSmithKline Plc Profiles
9.4.2 GlaxoSmithKline Plc Product Portfolio
9.4.3 GlaxoSmithKline Plc NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.4.4 GlaxoSmithKline Plc NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.5 Griffith University
9.5.1 Griffith University Profiles
9.5.2 Griffith University Product Portfolio
9.5.3 Griffith University NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.5.4 Griffith University NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.6 ImmunoBiology Ltd
9.6.1 ImmunoBiology Ltd Profiles
9.6.2 ImmunoBiology Ltd Product Portfolio
9.6.3 ImmunoBiology Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.6.4 ImmunoBiology Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.7 JN-International Medical Corp
9.7.1 JN-International Medical Corp Profiles
9.7.2 JN-International Medical Corp Product Portfolio
9.7.3 JN-International Medical Corp NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.7.4 JN-International Medical Corp NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.8 MGB Biopharma Ltd
9.8.1 MGB Biopharma Ltd Profiles
9.8.2 MGB Biopharma Ltd Product Portfolio
9.8.3 MGB Biopharma Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.8.4 MGB Biopharma Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.9 Panacea Biotec Ltd
9.9.1 Panacea Biotec Ltd Profiles
9.9.2 Panacea Biotec Ltd Product Portfolio
9.9.3 Panacea Biotec Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.9.4 Panacea Biotec Ltd NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.10 Pfizer Inc
9.10.1 Pfizer Inc Profiles
9.10.2 Pfizer Inc Product Portfolio
9.10.3 Pfizer Inc NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Performance
9.10.4 Pfizer Inc NEISSERIA MENINGITIDIS INFECTIONS DRUG Business Development and Market Status
9.11 Sanofi Pasteur SA
9.12 Serum Institute of India Ltd
9.13 Wellstat Vaccines LLC
10 World NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Assessment by Players
10.1 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales (K Units) and Market Share by Players 2014-2020
10.2 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Price (USD/Unit) of Players 2014-2020
10.4 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales Assessment of Players 2014-2020
11.1.2 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue Assessment of Players 2014-2020
11.1.3 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Price Assessment of Players 2014-2020
11.1.4 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales Assessment of Players 2014-2020
11.2.2 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Price Assessment of Players 2014-2020
11.2.4 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales Assessment of Players 2014-2020
11.4.2 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue Assessment of Players 2014-2020
11.4.3 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Price Assessment of Players 2014-2020
11.4.4 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific NEISSERIA MENINGITIDIS INFECTIONS DRUG Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales by Countries/Regions 2014-2020
12.2.2 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue by Countries/Regions 2014-2020
12.2.3 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales by Countries/Regions 2014-2020
12.3.2 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue by Countries/Regions 2014-2020
12.3.3 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales by Countries/Regions 2014-2020
12.4.2 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue by Countries/Regions 2014-2020
12.4.3 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales & Revenue Forecast 2021-2026
14.1 World NEISSERIA MENINGITIDIS INFECTIONS DRUG Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World NEISSERIA MENINGITIDIS INFECTIONS DRUGSales and Market Share by Regions
14.1.2 World NEISSERIA MENINGITIDIS INFECTIONS DRUGRevenue and Market Share by Regions
15 Asia NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 MGBBP-3
15.1.2 NCL-195
15.1.3 TP-10
15.1.4 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 MGBBP-3
16.1.2 NCL-195
16.1.3 TP-10
16.1.4 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 MGBBP-3
17.1.2 NCL-195
17.1.3 TP-10
17.1.4 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 MGBBP-3
18.1.2 NCL-195
18.1.3 TP-10
18.1.4 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa NEISSERIA MENINGITIDIS INFECTIONS DRUG Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 MGBBP-3
19.1.2 NCL-195
19.1.3 TP-10
19.1.4 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Price (USD/Unit) Trend 2021-2026
20.2 Global NEISSERIA MENINGITIDIS INFECTIONS DRUG Gross Profit Trend 2021-2026
21 Conclusion
